D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.
Michele Carbone,Ivano Amelio,El Bachir Affar,James Brugarolas,Lisa A. Cannon-Albright,Lisa A. Cannon-Albright,Lewis C. Cantley,Webster K. Cavenee,Zhijian J. Chen,Carlo M. Croce,Alan D’ Andrea,David R. Gandara,Carlotta Giorgi,Wei Jia,Qing Lan,Tak W. Mak,James L. Manley,Katsuhiko Mikoshiba,José N. Onuchic,Harvey I. Pass,Paolo Pinton,Carol Prives,Nathaniel Rothman,Said M. Sebti,James Turkson,Xifeng Wu,Haining Yang,Herbert Yu,Gerry Melino +28 more
TL;DR: There was general consensus that a better understanding of the complexity and numerosity of G × E interactions will further promote the understanding of cancer and lead to novel preventive and therapeutic approaches.
Journal ArticleDOI
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study
Ali Khojasteh,George P. Sartiano,Efstathios Tapazoglou,Eric P. Lester,David R. Gandara,Stephen A. Bernard,Andrew L. Finn +6 more
TL;DR: There is a parallel relationship between the ondansetron doses and the antiemetic efficacy, and the response rate for the six‐dose regimen was not superior to that for the previously reported 0.18 mg/kg regimen given in a three‐dose schedule in a similar clinical setting.
Journal ArticleDOI
Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
TL;DR: The standard of care for resected stage II-IIIA non-small cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens--the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and the Adjuance International Trialist Association trial.
Journal ArticleDOI
Current Status of Adjuvant Chemotherapy for Stage IB Non-Small-Cell Lung Cancer: Implications for the New Intergroup Trial
TL;DR: The next large intergroup adjuvant trial in non-small-cell lung cancer will look at bevacizumab in combination with chemotherapy, and will likely include only cisplatin-based regimens.
Journal ArticleDOI
Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126)
Wilbur A. Franklin,Kari Chansky,Paul H. Gumerlock,Fred R. Hirsch,Howard West,John Crowley,David R. Gandara +6 more
TL;DR: Low pMAPK(N) and combined low ErbB2 and p MAPK(n) predict increased survival with Gefitinib therapy in patients with advanced BAC and suggest that dual inhibition ofErbB1 and ErBB2 may lead to improved therapeutic efficacy.